iPSC banking, engineering, and differentiation into therapeutically relevant lineages — with the characterization and comparability work allogeneic programs demand.
Induced Pluripotent Stem Cell (iPSC) manufacturing reprograms somatic cells into induced pluripotent stem cells, banks and characterizes them under GMP, optionally engineers the line, then differentiates it into a therapeutic lineage such as iPSC-derived NK, T, or macrophage cells. Because a single well-characterized bank can supply many lots, iPSC platforms are the basis of most off-the-shelf allogeneic strategies — and everything downstream depends on how that bank was made and tested.
GeneFab is an iPSC CDMO for GMP iPSC banking and iPSC-derived cell manufacturing. We manufacture and characterize Engineering, Master, and Working iPSC banks, engineer lines at the pluripotent stage so every differentiated lot inherits the edit, transfer and optimize differentiation protocols, and run the comparability and GMP release testing that allogeneic programs demand.
iPSC programs enter with a research line, a GMP-intent line, or a differentiation protocol. These are the pieces we own.
Engineering, Master, and Working cell banks manufactured and characterized under GMP, with the documentation package regulators will ask for.
Engineering at the iPSC stage so every differentiated lot inherits the edit. Genetic circuit design from our synthetic biology group, with promoter and regulatory element selection appropriate to the target lineage.
Differentiation protocol transfer, optimization, and scale into therapeutically relevant lineages, with the purity and residual-undifferentiated-cell questions handled explicitly.
Lot-to-lot comparability across differentiated batches, and the characterization package that supports a change to the bank, the protocol, or the scale.
Closed wash, concentration, and cryopreservation into the final container, with post-thaw viability and lineage identity treated as release-relevant.
The bank is fixed; the differentiation process is where scale is won or lost. Development targets yield and purity per differentiation run, consistency as volumes increase, and the comparability package that supports a scale change without invalidating earlier lots.
Identity, purity, potency, and safety assays developed against the process, with core biosafety testing performed in house.
An iPSC-derived product is only as defensible as the bank it came from. Characterization, genomic stability, and documentation done properly at the bank stage remove a whole category of late-stage regulatory surprise.
Identity, genomic stability, and adventitious agent testing done at the bank, where it is cheap, not at the product, where it is not.
Edits made at the iPSC stage so every differentiated lot inherits them, with screening before commitment.
Lot-to-lot comparability treated as a designed exercise, not an argument assembled after the fact.
What sponsors ask before choosing a iPSC CDMO for a iPSC program.
Yes. We manufacture and characterize Engineering, Master, and Working iPSC banks under GMP, including identity, sterility, mycoplasma, adventitious agent, and genomic stability testing.
Yes. We transfer, optimize, and scale differentiation protocols into therapeutically relevant lineages, and develop the purity and lineage identity analytics alongside the process.
Yes. Engineering at the iPSC stage means every differentiated lot inherits the edit. Our synthetic biology group supports genetic circuit design and lineage-appropriate promoter selection, and we manufacture the vector.
Control of residual undifferentiated cells is treated as a defined process and analytical objective, with the assay developed alongside the differentiation process rather than after it.
Yes. Comparability is designed as an exercise up front — across banks, differentiated lots, protocol changes, and scale changes — rather than assembled retrospectively.
Yes. Differentiation is where an iPSC platform scales, so development targets yield and purity per run, consistency as volume increases, and the comparability package that supports a scale change without invalidating earlier lots.
A technical exchange under CDA, then a gap assessment of your line, protocol, and analytics, a tech transfer plan, and engineering runs before GMP. Requesting a quote starts that conversation.
